Pancreatic Neuroendocrine Tumor
Back to Diseases List
Associated Genetic Biomarkers
NCI Definition: A low or intermediate grade well differentiated tumor with neuroendocrine differentiation that arises from the pancreas. According to the presence or absence of clinical syndromes that result from hormone hypersecretion, pancreatic neuroendocrine tumors are classified either as functional or nonfunctional. 
Of the biomarker-directed therapies for pancreatic neuroendocrine tumor, 1 is FDA-approved in at least one setting and 0 have NCCN guidelines in at least one setting .
Lutetium Lu 177 Dotatate +
Disease is predicted to be sensitive: -
Sample must match all of the following:
|Clinical Setting(s): Metastatic (FDA)|
There are 19 clinical trials for pancreatic neuroendocrine tumor, of which 15 are open and 4 are completed or closed. Of the trials that contain pancreatic neuroendocrine tumor as an inclusion criterion, 1 is early phase 1 (1 open), 3 are phase 1 (3 open), 4 are phase 1/phase 2 (2 open), 10 are phase 2 (8 open), and 1 is phase 3 (1 open).
SSTR2, SSTR1, and SSTR3 are the most frequent gene inclusion criteria for pancreatic neuroendocrine tumor clinical trials .
Lutetium lu 177 dotatate, temozolomide, and 177lu-dota-octreotate are the most common interventions in pancreatic neuroendocrine tumor clinical trials.
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.